L02AE02 • leuprorelin • Antineoplastic and immunomodulating agents | Hormones and related agents | Gonadotropin releasing hormone analogues
Leuprorelin is a gonadotropin-releasing hormone (GnRH) agonist used for the treatment of prostate cancer, endometriosis, and precocious puberty. It works by suppressing the production of sex hormones, thereby reducing disease progression.
The medication is administered as a subcutaneous or intramuscular injection, usually once a month or at longer intervals, as directed by a doctor.
Side effects may include hot flashes, decreased libido, fatigue, or bone pain. In rare cases, severe allergic reactions or depression may occur.
Leuprorelin is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.
Substance: leuprorelin
Date of last drug list: 01-09-2021
Commercial code: W67840001
Concentration: 22.5mg
Pharmaceutical form: powder + solvent for suspension injection with prolonged release
Quantity: 1
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: GP-PHARM S.A. - SPANIA
Holder: GP-PHARM S.A. - SPANIA
Number: 12852/2019/01
Shelf life: 3 years-Dupa ambalare pentru comercializare;Dupa reconstituire-it is used immediately